JPMorgan Chase & Co. Decreases Position in Compugen Ltd. (NASDAQ:CGEN)

JPMorgan Chase & Co. lessened its position in Compugen Ltd. (NASDAQ:CGEN - Free Report) by 62.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 67,485 shares of the biotechnology company's stock after selling 113,287 shares during the quarter. JPMorgan Chase & Co. owned about 0.08% of Compugen worth $122,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its stake in Compugen by 75.9% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 8,350 shares in the last quarter. Joel Isaacson & Co. LLC increased its holdings in shares of Compugen by 136.4% in the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 30,000 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Compugen by 23.4% during the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company's stock worth $144,000 after buying an additional 16,253 shares during the last quarter. Atom Investors LP grew its holdings in Compugen by 27.5% in the 3rd quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company's stock valued at $275,000 after buying an additional 32,701 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Compugen by 82.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company's stock worth $497,000 after acquiring an additional 124,190 shares during the last quarter. 12.22% of the stock is owned by institutional investors and hedge funds.

Compugen Trading Down 1.9 %

Compugen stock traded down $0.05 during mid-day trading on Thursday, hitting $2.52. The company's stock had a trading volume of 1,085,455 shares, compared to its average volume of 1,050,669. The stock's fifty day moving average is $1.85 and its two-hundred day moving average is $1.79. The firm has a market capitalization of $224.88 million, a PE ratio of 126.00 and a beta of 2.65. Compugen Ltd. has a 1 year low of $1.35 and a 1 year high of $3.03.

Compugen (NASDAQ:CGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.21 by ($0.20). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The business had revenue of $17.13 million for the quarter, compared to analysts' expectations of $17.67 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. On average, equities analysts expect that Compugen Ltd. will post -0.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Oppenheimer began coverage on shares of Compugen in a report on Monday, January 13th. They issued an "outperform" rating and a $4.00 price objective for the company.

Compugen Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.